China SXT Pharmaceuticals issues warrants in USD 9 million registered direct offering
SXTC•China SXT Pharmaceuticals launches registered direct offering
China SXT Pharmaceuticals launched a registered direct offering of 4,500,000 units at USD 2 per unit for about USD 9 million gross.
Each unit includes one Class A ordinary share and one common warrant exercisable immediately at USD 3.2, expiring one year from issuance.
Closing is expected around July 24, 2025, subject to customary conditions.
